Biosimilars Market to Reach Upwards 143.7B by 2032
DataHorizzon Research anticipates an 18.1% CAGR through next decade.
According to DataHorizzon Research, the biosimilars market size was valued at $27.7 billion in 2022 and is expected to grow to a market size of $143.7 billion by 2032, with a compound annual growth rate (CAGR) of 18.1%.
The market is growing rapidly due to the increasing prevalence of chronic diseases. Additionally, biosimilars are in high demand due to drugs losing their patents, cost-effectiveness, and government efforts to reduce healthcare expenses.
Biosimilars, approved by FDA, are biologic products identical to reference products. They offer cost savings compared to original biological drugs, which provides another option for treating several acute and chronic diseases. They are gaining popularity due to the rising prevalence of chronic diseases and recent regulatory clearance in several countries.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
